Tech Company Financing Transactions
Rubedo Life Sciences Funding Round
Khosla Ventures, Longevity Fund and Refactor Capital participated in a $12 million Seed funding round for Rubedo Life Sciences. The round closed on 12/4/2020.
Transaction Overview
Company Name
Announced On
12/4/2020
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Seed
Investors
Proceeds Purpose
The funding will be used to advance the company's lead candidates in respiratory diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
228 Oakmead Pkwy.
Sunnyvale, CA 94085
USA
Sunnyvale, CA 94085
USA
Phone
Undisclosed
Website
Email Address
Overview
Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from leading biotech companies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Mark Gallop
Chief Executive Officer
Marco Quarta
Chief Technical Officer
Alex Laslavic
Co-Founder
Julian Klein
Vice President
Jeffrey Jasper
VP - R & D
Alberto Vitari
Browse more venture capital transactions:
Prev: 12/4/2020: GreenPark Sports venture capital transaction
Next: 12/4/2020: Sundae venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC investment data records on this site are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs